{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:03:33Z","timestamp":1786982613571,"version":"build-2736575974"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":504,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01223-w","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T13:06:14Z","timestamp":1652360774000},"page":"711-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-complement Agents for Autoimmune Neurological Disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Jennifer A.","family":"McCombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01223-w_bib1","doi-asserted-by":"crossref","first-page":"673339","DOI":"10.3389\/fneur.2021.673339","article-title":"Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management","volume":"12","author":"Sechi","year":"2021","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib2","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG. New hope for patients with neuromyelitis optica: From biomarker discovery to completion of phase 3 trials. Submitted. 2022."},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis - success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 3","key":"10.1007\/s13311-022-01223-w_bib4","first-page":"iii3","article-title":"History of modern multiple sclerosis therapy","volume":"252","author":"Lublin","year":"2005","journal-title":"J Neurol"},{"issue":"2\u20133","key":"10.1007\/s13311-022-01223-w_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0165-5728(92)90135-8","article-title":"Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma","volume":"40","author":"Olsson","year":"1992","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01223-w_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1007\/s13311-022-01223-w_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01223-w_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4049\/jimmunol.125.2.471","article-title":"Presidential address to American Association of Immunologists in Anaheim, California, April 16, 1980. Louis Pillemer, Properdin, and scientific controversy","volume":"125","author":"Lepow","year":"1980","journal-title":"J Immunol"},{"issue":"3","key":"10.1007\/s13311-022-01223-w_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.6.3.277","article-title":"Snake venom in relation to haemolysis, bacteriolysis and toxicity","volume":"6","author":"Flexner","year":"1902","journal-title":"J Exp Med"},{"issue":"4427","key":"10.1007\/s13311-022-01223-w_bib11","first-page":"161","article-title":"Flurry over venom","volume":"207","author":"Holden","year":"1980","journal-title":"Science"},{"issue":"2\u20134","key":"10.1007\/s13311-022-01223-w_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0161-5890(03)00111-1","article-title":"Complement therapeutics; history and current progress","volume":"40","author":"Morgan","year":"2003","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1007\/s13311-022-01223-w_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1007\/s13311-022-01223-w_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1007\/s13311-022-01223-w_bib15","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.4049\/jimmunol.180.9.5882","article-title":"IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production","volume":"180","author":"Liu","year":"2008","journal-title":"J Immunol"},{"issue":"Pt 7","key":"10.1007\/s13311-022-01223-w_bib16","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archneur.1991.00530130034016","article-title":"The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis","volume":"48","author":"Kissel","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib20","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1007\/s13311-022-01223-w_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"The Netherlands Neuromuscul Disord"},{"issue":"7","key":"10.1007\/s13311-022-01223-w_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","article-title":"Review: immune-mediated necrotizing myopathies\u2013a heterogeneous group of diseases with specific myopathological features","volume":"38","author":"Stenzel","year":"2012","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"10.1007\/s13311-022-01223-w_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1007\/s13311-022-01223-w_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib25","first-page":"e507","article-title":"Necrosis in anti-SRP","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01223-w_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","article-title":"Changes in serum complement activity in patients with myasthenia gravis","volume":"105","author":"Nastuk","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J Exp Med"},{"issue":"2","key":"10.1007\/s13311-022-01223-w_bib28","first-page":"78","article-title":"Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates","volume":"5","author":"Fazekas","year":"1986","journal-title":"Clin Neuropathol"},{"key":"10.1007\/s13311-022-01223-w_bib29","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41423-020-0388-9","article-title":"Physiology of gangliosides and the role of antiganglioside antibodies in human diseases","volume":"17","author":"Cutillo","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"10280","key":"10.1007\/s13311-022-01223-w_bib31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1007\/s13311-022-01223-w_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","article-title":"Acute motor axonal neuropathy: an antibody-mediated attack on axolemma","volume":"40","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01223-w_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/WCO.0000000000000725","article-title":"Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"32","author":"Pascual-Go\u00f1i","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib35","doi-asserted-by":"crossref","first-page":"637336","DOI":"10.3389\/fnins.2021.637336","article-title":"A systematic review and meta-analysis of autoantibodies for diagnosis and prognosis in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Guo","year":"2021","journal-title":"Front Neurosci"},{"issue":"408","key":"10.1007\/s13311-022-01223-w_bib36","doi-asserted-by":"crossref","first-page":"116576","DOI":"10.1016\/j.jns.2019.116576","article-title":"Antiganglioside antibodies in neurological diseases","volume":"15","author":"Wanleenuwat","year":"2020","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/jnnp-2017-317192","article-title":"Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground","volume":"89","author":"Uncini","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9451","key":"10.1007\/s13311-022-01223-w_bib38","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"24","key":"10.1007\/s13311-022-01223-w_bib40","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1007\/s13311-022-01223-w_bib41","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneurol.2009.188","article-title":"Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells","volume":"66","author":"Hinson","year":"2009","journal-title":"Arch Neurol"},{"issue":"Pt 2","key":"10.1007\/s13311-022-01223-w_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12974-018-1333-z","article-title":"Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica","volume":"15","author":"Duan","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1007\/s13311-022-01223-w_bib46","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"129","author":"Soltys","year":"2019","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1007\/s13311-022-01223-w_bib47","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3389\/fimmu.2018.01694","article-title":"C5a-preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder","volume":"23","author":"Piatek","year":"2018","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-022-01223-w_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2018.06.008","article-title":"Developments in anti-complement therapy; from disease to clinical trial","volume":"102","author":"Harris","year":"2018","journal-title":"Mol Immunol"},{"issue":"11","key":"10.1007\/s13311-022-01223-w_bib49","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.3390\/ijms22115755","article-title":"Fc-receptor targeted therapies for the treatment of Myasthenia gravis","volume":"22","author":"Keller","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1007\/s13311-022-01223-w_bib50","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"8","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1007\/s13311-022-01223-w_bib51","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3899\/jrheum.180060","article-title":"Complement C5-blocking agent in refractory dermatomyositis","volume":"45","author":"Faguer","year":"2018","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1007\/s13311-022-01223-w_bib53","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1007\/s13311-022-01223-w_bib55","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-022-01223-w_bib56","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1007\/s13311-022-01223-w_bib57","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420911784","article-title":"Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study","volume":"13","author":"Jacob","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"10.1007\/s13311-022-01223-w_bib59","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib60","doi-asserted-by":"crossref","first-page":"556104","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the","volume":"11","author":"Nowak","year":"2020","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib61","doi-asserted-by":"crossref","first-page":"116419","DOI":"10.1016\/j.jns.2019.08.004","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study","volume":"407","author":"Murai","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01223-w_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211001995","article-title":"Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance","volume":"14","author":"Murai","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1007\/s13311-022-01223-w_bib63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JND-200584","article-title":"Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib65","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01223-w_bib66","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib67","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01223-w_bib68","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01223-w_bib69","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.msard.2020.102641","article-title":"Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial","volume":"47","author":"Palace","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"10.1007\/s13311-022-01223-w_bib70","doi-asserted-by":"crossref","first-page":"102849","DOI":"10.1016\/j.msard.2021.102849","article-title":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","volume":"50","author":"Kim","year":"2021","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib71","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib72","doi-asserted-by":"crossref","unstructured":"Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, et al. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler. 2021:13524585211038291.","DOI":"10.1177\/13524585211038291"},{"issue":"2","key":"10.1007\/s13311-022-01223-w_bib73","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/14740338.2021.1857723","article-title":"Safety of current treatments for paroxysmal nocturnal hemoglobinuria","volume":"20","author":"Lee","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"10.1007\/s13311-022-01223-w_bib74","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2020002497","article-title":"Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients","volume":"4","author":"Langereis","year":"2020","journal-title":"Blood Adv"},{"key":"10.1007\/s13311-022-01223-w_bib75","doi-asserted-by":"crossref","unstructured":"Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F, REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve. 2021.","DOI":"10.1002\/mus.27422"},{"issue":"5","key":"10.1007\/s13311-022-01223-w_bib76","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib77","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1212\/NXI.0000000000000005","article-title":"Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica","volume":"1","author":"Levy","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"10.1007\/s13311-022-01223-w_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106824","article-title":"Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model","volume":"9","author":"Tradtrantip","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1007\/s13311-022-01223-w_bib79","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1212\/NXI.0000000000000689","article-title":"Complement factor I deficiency: a potentially treatable cause of fulminant cerebral inflammation","volume":"7","author":"Altmann","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1007\/s13311-022-01223-w_bib80","doi-asserted-by":"crossref","unstructured":"Kawamoto M, Murakami Y, Kinoshita T, Kohara N. Recurrent aseptic meningitis with PIGT mutations: a novel pathogenesis of recurrent meningitis successfully treated by eculizumab. BMJ Case Rep. 2018;2018:bcr2018225910.","DOI":"10.1136\/bcr-2018-225910"},{"issue":"5","key":"10.1007\/s13311-022-01223-w_bib81","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ana.24770","article-title":"Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation","volume":"80","author":"Mevorach","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01223-w_bib82","unstructured":"Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG). 2021. In: StatPearls."},{"issue":"6","key":"10.1007\/s13311-022-01223-w_bib83","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0000000000000609","article-title":"New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases","volume":"27","author":"Norris","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"10.1007\/s13311-022-01223-w_bib84","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1007\/s13311-022-01223-w_bib85","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","article-title":"Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria","volume":"60","author":"Badri","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1007\/s13311-022-01223-w_bib86","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/acsomega.9b03735","article-title":"preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice","volume":"5","author":"Kumar","year":"2020","journal-title":"ACS Omega"},{"key":"10.1007\/s13311-022-01223-w_bib87","doi-asserted-by":"crossref","unstructured":"Mastellos DC, Ricklin D, Sfyroera G, Sahu A. From discovery to approval: a brief history of the compstatin family of complement C3 inhibitors. Clin Immunol. 2021:108785.","DOI":"10.1016\/j.clim.2021.108785"},{"issue":"11","key":"10.1007\/s13311-022-01223-w_bib88","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1007\/s13311-022-01223-w_bib89","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12974-019-1448-x","article-title":"CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica","volume":"16","author":"Tradtrantip","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"14","key":"10.1007\/s13311-022-01223-w_bib90","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01223-w_bib91","doi-asserted-by":"crossref","first-page":"712572","DOI":"10.3389\/fimmu.2021.712572","article-title":"Complement factor D as a strategic target for regulating the alternative complement pathway","volume":"12","author":"Barratt","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1007\/s13311-022-01223-w_bib92","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1007\/s13311-022-01223-w_bib93","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1212\/NXI.0000000000000075","article-title":"Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis","volume":"2","author":"K\u00f6rtvelyessy","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"Pt 8","key":"10.1007\/s13311-022-01223-w_bib94","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonz\u00e1lez","year":"2014","journal-title":"Brain"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01223-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:08Z","timestamp":1761807428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S187874792301098X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01223-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-complement Agents for Autoimmune Neurological Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01223-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}